To evaluate relapses in patients with breast cancer (BC) who underwent radical subcutaneous mastectomy with simultaneous reconstruction.
From 2013 to 2017 radical subcutaneous mastectomies were performed with various types of reconstructions in 472 patients with BC. Reconstruction was carried out by autotissues (15%), as well as expanders, followed by replacement with endoprostheses, as well as a combination of endoprostheses with or without patch (85%). Distribution by patients’ cancer stage: 0 – 5,5%, I – 30,7%, IIA – 28,6%, IIB – 14,8%, IIIA – 13,8%, IIIC – 4,9 %, IIIB – 1,7%. The distribution by biological types of BC is as follows: luminal A - 165 (37%), luminal B - 84 (18,8%), luminal B her2 positive - 74 (16,6%), triple negative - 81 (18,2 %), her2-positive - 42 (9,4%).
The timing of relapse ranged from 0,8 to 5,5 years. In 1 case, a local recurrence was diagnosed simultaneously with distant metastases. A total of 9 patients were diagnosed with a relapse: in 4 cases a local and in 4 cases a regional relapse, and in 1 case a locoregional relapse. Treatment of BC recurrence was as follows: in two cases, polychemotherapy courses were performed, in 6 cases operations were performed - excision of the recurrence in the mammary gland (4), removal of the mammary gland (2), in 1 case - radiation therapy. Metastases were diagnosed in 21 (4,4%) patients. The overall 3 year survival rate was 97,8%. In 13%, relapses were diagnosed in stage IIIC of breast cancer, the lowest percentage of relapses was 0,7% in stage I and IIA. In the case of luminal type A, relapse was diagnosed in 1,8%, in the case of luminal B 2,4%, in the case of the triple negative type 2,5%, and in the case of luminal B her 2 positive - 2,7%. In a multicentric BC, relapse was diagnosed in 5,5%, in a monocentric tumor in 1,5% (p < 0,05).
1) relapses of BC were diagnosed in 9 (1,9 ± 0,6%) cases. 2) distribution of relapses by molecular-biological types of BC: luminal A – 1,8%, B – 2,4%, triple negative – 2,5%, luminal B her2-positive – 2,7%; 3) metastasis of BC was diagnosed in 21 (4,4 ± 0,9%) cases, in 50% metastases were detected in the brain and lungs; 4) 3-year overall survival of patients with BC was 97,8% (n = 269).
Rasskazova E.
Has not received any funding.
All authors have declared no conflicts of interest.